Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center

(2013) A. Gibb et al.   HAEMATOLOGICA

Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma

(2013) Sylvain Garciaz et al.   HEMATOLOGICAL ONCOLOGY

Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease

(2013) Urszula Sobol et al.   LEUKEMIA & LYMPHOMA

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

(2013) Sally Arai et al.   LEUKEMIA & LYMPHOMA

Patients' and physicians' roles in detecting recurrent Hodgkin lymphoma following complete remission

(2012) A. Bestawros et al.   ANNALS OF ONCOLOGY

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

(2012) R. Chen et al.   BLOOD

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma

(2011) Robert Chen et al.   ANNALS OF HEMATOLOGY

Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs

(2011) T. C. El-Galaly et al.   HAEMATOLOGICA

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2011) A. Sureda et al.   HAEMATOLOGICA

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

(2010) B. Sarina et al.   BLOOD

Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management

(2010) M. Gerlinger et al.   HAEMATOLOGICA

Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma

(2009) Marcel P. Devetten et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non-Hodgkin Lymphoma: Importance of Histology for Outcome

(2008) Philippe Armand et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma

(2008) Lauri M. Burroughs et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

(2008) P. Anderlini et al.   HAEMATOLOGICA

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

(2008) S. P. Robinson et al.   HAEMATOLOGICA

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2007) Anna Sureda et al.   JOURNAL OF CLINICAL ONCOLOGY